Plain-English translation of NCT06441955 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers are studying how to better understand and treat long COVID—the ongoing symptoms some people experience long after their initial COVID-19 infection. The trial will test two approaches: either the or Paxlovid (an antiviral medication) to see which may help reduce your persistent symptoms like breathing problems or neurological issues.
Many people continue to suffer from exhaustion, brain fog, shortness of breath, and other debilitating symptoms months or years after COVID-19. This trial aims to find effective treatments for these lingering problems and to identify biological markers that could help doctors predict who is at risk and personalize care.
You likely qualify if…
You likely don't qualify if…
You will have an intake assessment to confirm your eligibility. Depending on which group you're assigned to, you'll either receive two doses of the Moderna vaccine one month apart, or you'll receive a course of the antiviral medication Paxlovid. Throughout the study, researchers will collect blood samples and other data to identify biological markers linked to long COVID and to measure whether your symptoms improve. You'll need to attend follow-up appointments as scheduled by the study team.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States